JSAM
KROS icon

J. Safra Asset Management’s Keros Therapeutics KROS Stock Holding History

J. Safra Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8
Closed -$125 – 371
2024
Q4 		$125 Buy
8
+2
+33% +$104 ﹤0.01% 340
2024
Q3 		$339 Buy
+6
New +$296 ﹤0.01% 294

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Safra Asset Management's KROS Position: Q1 2025 in Review

J. Safra Asset Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 8 shares — an estimated $125 sold.

J. Safra Asset Management first reported a position in KROS in Q3 2024 and held it in 2 quarters. The position peaked at $339 in Q3 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • J. Safra Asset Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • J. Safra Asset Management sold 8 Keros Therapeutics shares in Q1 2025, an estimated $125.
  • J. Safra Asset Management first reported a position in Keros Therapeutics in Q3 2024 and held it in 2 quarters.
  • J. Safra Asset Management's Keros Therapeutics position peaked at $339 in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on J. Safra Asset Management's 13F filing for Q1 2025, filed 25 Apr 2025.